Johnson & Johnson (JNJ) Position Cut by Tealwood Asset Management Inc.

Tealwood Asset Management Inc. decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 24.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 34,856 shares of the company’s stock after selling 11,071 shares during the period. Johnson & Johnson comprises approximately 1.7% of Tealwood Asset Management Inc.’s holdings, making the stock its 15th largest position. Tealwood Asset Management Inc.’s holdings in Johnson & Johnson were worth $4,611,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of JNJ. Lau Associates LLC boosted its position in shares of Johnson & Johnson by 12.8% in the first quarter. Lau Associates LLC now owns 46,878 shares of the company’s stock valued at $5,839,000 after buying an additional 5,335 shares in the last quarter. Loomis Sayles & Co. L P boosted its position in Johnson & Johnson by 396.7% in the fourth quarter. Loomis Sayles & Co. L P now owns 110,823 shares of the company’s stock worth $12,768,000 after buying an additional 88,510 shares in the last quarter. Jackson Grant Investment Advisers Inc. boosted its position in Johnson & Johnson by 7.3% in the fourth quarter. Jackson Grant Investment Advisers Inc. now owns 14,124 shares of the company’s stock worth $1,627,000 after buying an additional 957 shares in the last quarter. Burke & Herbert Bank & Trust Co. boosted its position in Johnson & Johnson by 2.6% in the first quarter. Burke & Herbert Bank & Trust Co. now owns 47,330 shares of the company’s stock worth $5,895,000 after buying an additional 1,218 shares in the last quarter. Finally, Independent Advisor Alliance bought a new position in Johnson & Johnson during the fourth quarter worth approximately $4,035,000. 66.06% of the stock is owned by institutional investors.

Johnson & Johnson (NYSE:JNJ) traded up 0.02% during midday trading on Thursday, reaching $133.26. 1,484,341 shares of the company were exchanged. The firm has a market capitalization of $357.67 billion, a PE ratio of 22.55 and a beta of 0.78. Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $137.08. The company has a 50-day moving average of $133.23 and a 200 day moving average of $126.11.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, beating analysts’ consensus estimates of $1.79 by $0.04. The firm had revenue of $18.84 billion during the quarter, compared to analyst estimates of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. Johnson & Johnson’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same period last year, the firm posted $1.74 earnings per share. Equities analysts predict that Johnson & Johnson will post $7.18 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 2.52%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s payout ratio is 56.76%.

TRADEMARK VIOLATION WARNING: This story was posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/2800631/johnson-johnson-jnj-position-cut-by-tealwood-asset-management-inc.html.

A number of equities analysts have commented on JNJ shares. Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $128.54 price target for the company in a research note on Monday, April 24th. Cowen and Company reissued a “buy” rating and issued a $143.00 price target (up previously from $138.00) on shares of Johnson & Johnson in a research note on Friday, May 19th. UBS AG reissued a “buy” rating and issued a $136.00 price target on shares of Johnson & Johnson in a research note on Monday, May 15th. BMO Capital Markets reissued a “buy” rating and issued a $132.00 price target on shares of Johnson & Johnson in a research note on Friday, June 2nd. Finally, Royal Bank Of Canada reissued a “buy” rating and issued a $128.00 price target on shares of Johnson & Johnson in a research note on Thursday, June 15th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $133.72.

In other Johnson & Johnson news, VP Dominic J. Caruso sold 82,591 shares of Johnson & Johnson stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the completion of the transaction, the vice president now directly owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Paulus Stoffels sold 102,692 shares of Johnson & Johnson stock in a transaction on Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the transaction, the vice president now directly owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.